Maravai LifeSciences Holdings, Inc.MM

Maravai LifeSciences Holdings, Inc.

2.39USDR
+0.22+10.14%
At close at Jun 6, 21:07 GMT
USD
No trades
See on Supercharts

MRVI fundamentals

Key facts

Market capitalization‪608.64 M‬USD
Basic EPS (TTM)−1.15USD
Founded2014
CEOWilliam Martin
About

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Ownership
‪‪143.97 M‬‬
Free Float shares
‪‪107.06 M‬‬ (74.36%)
Closely held shares
‪‪36.91 M‬‬ (25.64%)
Free Float shares
‪‪107.06 M‬‬ (74.36%)
Closely held shares
‪‪36.91 M‬‬ (25.64%)
Capital structure
Market cap
‪‪608.64 M‬‬
Debt
‪‪326.65 M‬‬
Minority interest
‪‪229.66 M‬‬
Cash & equivalents
‪‪285.05 M‬‬
Enterprise value
‪‪879.90 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪608.64 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
1.29x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
1.29x
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪1.10‬
‪2.20‬
‪3.30‬
‪4.40‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−170%‬
‪−130%‬
‪−90%‬
‪−50%‬
‪−10%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−100.00 M‬‬
‪‪−50.00 M‬‬
‪0.00‬
‪‪50.00 M‬‬
‪‪100.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−60.00 M‬‬
‪‪−30.00 M‬‬
‪0.00‬
‪‪30.00 M‬‬
‪‪60.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−50.00 M‬‬
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬
‪‪50.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Nucleic Acid Production
Biologics Safety Testing
By country
Period: 2024
United States
Asia Pacific
Europe, the Middle East and Africa
Latin and Central America
North America

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪20.00 M‬‬
‪‪40.00 M‬‬
‪‪60.00 M‬‬
‪‪80.00 M‬‬
Actual
Estimate
Earnings
Next:Aug 12, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪−0.09‬
‪−0.06‬
‪−0.03‬
‪0.00‬
‪0.03‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

No dividends
MRVI has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−200.00 M‬‬
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪150.00 M‬‬
‪‪300.00 M‬‬
‪‪450.00 M‬‬
‪‪600.00 M‬‬
Assets
Liabilities